Stock Events

Stock Events

NeuroSense Therapeutics 

$0.21
11
+$0.04+26.79% Tuesday 13:30

Statistics

Day High
0.21
Day Low
0.21
52W High
0.21
52W Low
0.15
Volume
-
Avg. Volume
-
Mkt Cap
5.12M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22JunExpected
Q3 2024
Q1 2025
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.22
-0.16
-0.1
-0.04
Expected EPS
-0.0847
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-20.42MNet Income

Analyst Ratings

8.5Average Price Target
The highest estimate is 14.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NRSNW. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.62B
Biogen focuses on neurodegenerative diseases, directly competing with NeuroSense's ALS and Alzheimer's treatments.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, including therapies for neurological diseases that overlap with NeuroSense's focus areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for genetic and neurodegenerative diseases, competing in the same therapeutic areas as NeuroSense.
Palatin Technologies
PTN
Mkt Cap35.85M
Palatin Technologies is involved in developing therapeutics for diseases with a focus on neurological and inflammatory diseases, areas that NeuroSense is also targeting.
Anavex Life Sciences
AVXL
Mkt Cap307.67M
Anavex Life Sciences Corp. focuses on developing novel therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, directly competing with NeuroSense.
Axsome Therapeutics
AXSM
Mkt Cap10.62B
Axsome Therapeutics develops therapies for central nervous system disorders, including conditions that NeuroSense targets, making them competitors.
AnaptysBio
ANAB
Mkt Cap1.94B
AnaptysBio focuses on developing antibody-based therapies for inflammation and neurodegenerative diseases, areas that overlap with NeuroSense's therapeutic interests.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.76B
ACADIA Pharmaceuticals specializes in central nervous system disorders, with a portfolio that includes treatments for conditions NeuroSense is also aiming to treat.

About

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Show more...
CEO
Mr. Alon Ben-Noon
Employees
17
Country
Israel
ISIN
IL0011811630

Listings

F
DE
H1Z.F
XNAS
US
NRSN
XNAS
US
NRSNW
BOATS
BOATS
NRSN.BOATS

0 Comments

Share your thoughts

FAQ

What is NeuroSense Therapeutics stock price today?▼
The current price of NRSNW is $0.21 USD — it has increased by +26.79% in the past 24 hours. Watch NeuroSense Therapeutics stock price performance more closely on the chart.
What is NeuroSense Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange NeuroSense Therapeutics stocks are traded under the ticker NRSNW.
What is NeuroSense Therapeutics market cap?▼
Today NeuroSense Therapeutics has the market capitalization of 5.12M
When is the next NeuroSense Therapeutics earnings date?▼
NeuroSense Therapeutics is going to release the next earnings report on June 22, 2026.
What were NeuroSense Therapeutics earnings last quarter?▼
NRSNW earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.07 USD resulting in a -210.73% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is NeuroSense Therapeutics revenue for the last year?▼
NeuroSense Therapeutics revenue for the last year amounts to 0 USD.
What is NeuroSense Therapeutics net income for the last year?▼
NRSNW net income for the last year is -20.42M USD.
How many employees does NeuroSense Therapeutics have?▼
As of May 06, 2026, the company has 17 employees.
In which sector is NeuroSense Therapeutics located?▼
NeuroSense Therapeutics operates in the Health & Wellness sector.
When did NeuroSense Therapeutics complete a stock split?▼
NeuroSense Therapeutics has not had any recent stock splits.
Where is NeuroSense Therapeutics headquartered?▼
NeuroSense Therapeutics is headquartered in Herzliya, Israel.